156 related articles for article (PubMed ID: 37831182)
1. Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.
Tahata Y; Hikita H; Mochida S; Enomoto N; Ido A; Kuroda H; Miki D; Kurosaki M; Hiasa Y; Sakamori R; Kawada N; Yamashita T; Suda G; Yatsuhashi H; Yoshiji H; Kato N; Takami T; Nakao K; Matsuura K; Asahina Y; Itoh Y; Tateishi R; Nakamoto Y; Kakazu E; Terai S; Shimizu M; Ueno Y; Akuta N; Miyazaki M; Nozaki Y; Kabayama M; Sobue S; Moriuchi A; Miyaki T; Kodama T; Tatsumi T; Yamada T; Takehara T
J Gastroenterol; 2023 Dec; 58(12):1211-1221. PubMed ID: 37831182
[TBL] [Abstract][Full Text] [Related]
2. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
[TBL] [Abstract][Full Text] [Related]
3. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
El-Sherif O; Jiang ZG; Tapper EB; Huang KC; Zhong A; Osinusi A; Charlton M; Manns M; Afdhal NH; Mukamal K; McHutchison J; Brainard DM; Terrault N; Curry MP
Gastroenterology; 2018 Jun; 154(8):2111-2121.e8. PubMed ID: 29535028
[TBL] [Abstract][Full Text] [Related]
4. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.
Tahata Y; Hikita H; Mochida S; Kawada N; Enomoto N; Ido A; Yoshiji H; Miki D; Hiasa Y; Takikawa Y; Sakamori R; Kurosaki M; Yatsuhashi H; Tateishi R; Ueno Y; Itoh Y; Yamashita T; Kanto T; Suda G; Nakamoto Y; Kato N; Asahina Y; Matsuura K; Terai S; Nakao K; Shimizu M; Takami T; Akuta N; Yamada R; Kodama T; Tatsumi T; Yamada T; Takehara T
J Gastroenterol; 2021 Jan; 56(1):67-77. PubMed ID: 33001338
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
[TBL] [Abstract][Full Text] [Related]
6. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
Verna EC; Morelli G; Terrault NA; Lok AS; Lim JK; Di Bisceglie AM; Zeuzem S; Landis CS; Kwo P; Hassan M; Manns MP; Vainorius M; Akushevich L; Nelson DR; Fried MW; Reddy KR
J Hepatol; 2020 Sep; 73(3):540-548. PubMed ID: 32243960
[TBL] [Abstract][Full Text] [Related]
7. Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis.
Tahata Y; Hikita H; Mochida S; Enomoto N; Kawada N; Kurosaki M; Ido A; Miki D; Yoshiji H; Takikawa Y; Sakamori R; Hiasa Y; Nakao K; Kato N; Ueno Y; Yatsuhashi H; Itoh Y; Tateishi R; Suda G; Takami T; Nakamoto Y; Asahina Y; Matsuura K; Yamashita T; Kanto T; Akuta N; Terai S; Shimizu M; Sobue S; Miyaki T; Moriuchi A; Yamada R; Kodama T; Tatsumi T; Yamada T; Takehara T
J Gastroenterol; 2022 Feb; 57(2):120-132. PubMed ID: 35059853
[TBL] [Abstract][Full Text] [Related]
8. Early liver function improvement following successful treatment of chronic hepatitis C in patients with decompensated cirrhosis: a real-life study.
Lourenço MS; Zitelli PMY; Cunha-Silva M; Oliveira AIN; Lima RGR; Souza EO; Oliveira CP; Sevá-Pereira T; Carrilho FJ; Pessoa MG; Mazo DF
Clinics (Sao Paulo); 2021; 76():e3186. PubMed ID: 34817045
[TBL] [Abstract][Full Text] [Related]
9. Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers.
Sandmann L; Dörge P; Wranke A; Vermehren J; Welzel TM; Berg CP; Grottenthaler JM; Weiss KH; Langel J; Sterneck M; von Wulffen M; Manns MP; Wedemeyer H; Hardtke S; von Hahn T
Eur J Gastroenterol Hepatol; 2019 Aug; 31(8):1049-1056. PubMed ID: 30807443
[TBL] [Abstract][Full Text] [Related]
10. Direct antiviral therapy for hepatitis C cirrhotic patients in liver transplantation settings: a systematic review.
Li J; Wu V; Pan CQ
Hepatol Int; 2022 Oct; 16(5):1020-1031. PubMed ID: 36085539
[TBL] [Abstract][Full Text] [Related]
11. Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre- or post-liver transplant.
Peters MG; Kottilil S; Terrault N; Amara D; Husson J; Huprikar S; Florman S; Sulkowski MS; Durand CM; Luetkemeyer AF; Rogers R; Grab J; Haydel B; Blumberg E; Dove L; Emond J; Olthoff K; Smith C; Fishbein T; Masur H; Stock PG
Am J Transplant; 2021 May; 21(5):1780-1788. PubMed ID: 33277801
[TBL] [Abstract][Full Text] [Related]
12. Outcome of hepatitis C-related liver transplantation in direct-acting antiviral era.
Choudhary NS; Saraf N; Saigal S; Rastogi A; Bhangui P; Thiagrajan S; Soin AS
Indian J Gastroenterol; 2020 Dec; 39(6):539-543. PubMed ID: 33230754
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study.
Pereira GH; Peixoto HR; Giusti ML; Souza ML; Victor LB; Fernandes F; Perez RM; Villela-Nogueira CA
Braz J Infect Dis; 2022; 26(5):102697. PubMed ID: 36037847
[TBL] [Abstract][Full Text] [Related]
14. Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
Tada T; Kurosaki M; Nakamura S; Hasebe C; Kojima Y; Furuta K; Kobashi H; Kimura H; Ogawa C; Yagisawa H; Uchida Y; Joko K; Akahane T; Arai H; Marusawa H; Narita R; Ide Y; Sato T; Kusakabe A; Tsuji K; Mori N; Kondo M; Mitsuda A; Izumi N
J Med Virol; 2021 Nov; 93(11):6247-6256. PubMed ID: 34170517
[TBL] [Abstract][Full Text] [Related]
15. Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.
Liu CH; Chen CY; Su WW; Liu CJ; Lo CC; Huang KJ; Chen JJ; Tseng KC; Chang CY; Peng CY; Shih YL; Huang CS; Kao WY; Yang SS; Tsai MC; Wu JH; Chen PY; Su PY; Hwang JJ; Fang YJ; Lee PL; Tseng CW; Lee FJ; Lai HC; Hsieh TY; Chang CC; Chang CH; Huang YJ; Kao JH
Clin Mol Hepatol; 2021 Oct; 27(4):575-588. PubMed ID: 34255961
[TBL] [Abstract][Full Text] [Related]
16. Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?
Meunier L; Belkacemi M; Pageaux GP; Radenne S; Vallet-Pichard A; Houssel-Debry P; Duvoux C; Botta-Fridlund D; de Ledinghen V; Conti F; Anty R; Di Martino V; Debette-Gratien M; Leroy V; Gerster T; Lebray P; Alric L; Abergel A; Dumortier J; Besch C; Montialoux H; Samuel D; Duclos-Vallée JC; Coilly A
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680177
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.
Fernández Carrillo C; Lens S; Llop E; Pascasio JM; Crespo J; Arenas J; Fernández I; Baliellas C; Carrión JA; de la Mata M; Buti M; Castells L; Albillos A; Romero M; Turnes J; Pons C; Moreno-Planas JM; Moreno-Palomares JJ; Fernández-Rodriguez C; García-Samaniego J; Prieto M; Fernández Bermejo M; Salmerón J; Badia E; Salcedo M; Herrero JI; Granados R; Blé M; Mariño Z; Calleja JL
Hepatology; 2017 Jun; 65(6):1810-1822. PubMed ID: 28170112
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
[TBL] [Abstract][Full Text] [Related]
19. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.
Younossi ZM; Stepanova M; Feld J; Zeuzem S; Sulkowski M; Foster GR; Mangia A; Charlton M; O'Leary JG; Curry MP; Nader F; Henry L; Hunt S
Clin Gastroenterol Hepatol; 2017 Mar; 15(3):421-430.e6. PubMed ID: 27847279
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
Takehara T; Sakamoto N; Nishiguchi S; Ikeda F; Tatsumi T; Ueno Y; Yatsuhashi H; Takikawa Y; Kanda T; Sakamoto M; Tamori A; Mita E; Chayama K; Zhang G; De-Oertel S; Dvory-Sobol H; Matsuda T; Stamm LM; Brainard DM; Tanaka Y; Kurosaki M
J Gastroenterol; 2019 Jan; 54(1):87-95. PubMed ID: 30203225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
